Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On November 13, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 firs
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated November 13, 2025 104 Cover Page Interactive Data F